1. Background {#sec1}
=============

In the United States, New Jersey (NJ) was second only to the state of New York in the number of COVID-19 cases until June 2020 \[[@bib1]\]. Patients with severe COVID-19 can develop ventilator-dependent acute hypoxic respiratory failure (VDAHRF), which is associated with a higher mortality rate. Older age, male sex, D-dimer greater than 1 μg/mL, high Sequential Organ Failure Assessment (SOFA) score, and lower lymphocyte count have been linked with poor outcomes in COVID-19 \[[@bib2],[@bib3]\]. Data regarding successful extubation in COVID-19 is still evolving. We evaluated the clinical course of hospitalized COVID-19 patients. Characteristics of intubated patients who were successfully weaned from the ventilator were compared with patients who failed to be extubated or died in the hospital. An observational study from Wuhan, China with complete follow-up in patients who received invasive mechanical ventilation reported a mortality rate of 97%. Comparatively, an observational study from New York with incomplete follow up reported a lower mortality rate among intubated patients \[[@bib3],[@bib4]\]. To our knowledge, this is the first observational study from New Jersey that characterized the clinical picture of hospitalized COVID-19 patients, evaluated their clinical course, and studied possible predictors of intubation.

2. Objective {#sec2}
============

To investigate the clinical course of hospitalized COVID-19 patients, and assess the possible predictors of the disease severity leading to ventilator-dependent acute hypoxic respiratory failure (VDAHRF).

3. Methods {#sec3}
==========

This is a single-center institutional review board (IRB) approved, retrospective study. Inclusion criteria were adults 18 years of age or older who had RT-PCR confirmed SARS-CoV-2 infection. These were the first 129 patients with COVID-19 admitted to Monmouth Medical Center from March 1st to April 25th, 2020. The final date of follow-up to monitor clinical outcomes was May 2, 2020. Clinical characteristics of the patients who received invasive mechanical ventilation were compared to the patients who did not receive invasive mechanical ventilation ([Table-1](#tbl1){ref-type="table"} ). Clinical characteristics of the patients who were successfully weaned from the ventilator were compared to the patients who failed to be extubated ([Table-2](#tbl2){ref-type="table"} ). Data were extracted manually using the hospital electronic medical record. Multivariate logistic regression was modeled following stepwise selection to choose the best predictors. Odds ratio with 95% confidence intervals were calculated. Categorical variables were compared by conducting chi-square test or Fisher\'s exact test while continuous ones were compared by conducting median two-sample test. A standard two-sample *t*-test; two-sided and unpaired was used. F test was used for equal variances. Multiple imputation was used to handle the missing data. The *P*-value of \<0.05 was considered significant. Statistical analysis was done with SAS software.Table 1Characteristics of all hospitalized patients with COVID-19.Table 1Characteristicsp-valueAll Patients (n = 129)Patients who received invasive mechanical ventilation (n = 30)Patients who did not require invasive mechanical ventilation (n = 99)**Demographic**Median age (IQR), years0.220163.0 (45.0--72.0)65.5 (57.0--71.0)60.0 (39.0--72.0)Males-n, (%)0.007981 (62.8%)25 (83.3%)56 (56.6%)Caucasian-n, (%)0.021679 (61.2%)13 (43.3%)66 (66.7%)**Presentation**Median duration of symptoms prior to hospitalization (IQR), days0.43416.0 (3.0--9.0)6.0 (3.0--10.0)7.0 (3.0--9.0)Fever-n, (%)0.5123102 (79.1%)25 (83.3%)77 (77.8%)Dry cough-n, (%)0.221281 (62.8%)16 (53.3%)65 (65.7%)Productive cough-n, (%)0.526616 (12.4%)5 (16.7%)11 (11.1%)Dyspnea-n, (%)0.074172 (55.8%)21 (70.0%)51 (51.5%)Malaise-n, (%)0.310250 (38.8%)14 (46.7%)36 (36.4%)Nausea-n, (%)0.731313 (10.1%)2 (6.7%)11 (11.1%)Vomiting-n, (%)0.19678 (6.2%)0 (0%)8 (8.1%)Diarrhea-n, (%)0.310226 (20.2%)8 (26.7%)18 (18.2%)Poor appetite-n, (%)0.732419 (14.7%)5 (16.7%)14 (14.1%)Sore throat-n, (%)0.052010 (7.8%)5 (16.7%)5 (5.1%)Headache-n, (%)0.918731 (24.0%)7 (23.3%)24 (24.2%)Anosmia-n, (%)0.23074 (3.1%)2 (6.7%)2 (2.0%)Altered mental status-n, (%)0.62286 (4.7%)2 (6.7%)4 (4.0%)**Comorbidities**Heart failure-n, (%)0.731312 (9.3%)2 (6.7%)10 (10.1%)Hypertension-n, (%)0.681356 (43.4%)14 (46.7%)42 (42.4%)Coronary artery disease-n, (%)0.240210 (7.8%)4 (13.3%)6 (6.1%)Diabetes mellitus-n, (%)0.006325 (19.4%)11 (36.7%)14 (14.1%)Chronic obstructive pulmonary disease-n, (%)0.43349 (7.0%)3 (10.0%)6 (6.1%)Obesity-n, (%)0.033418 (14.0%)8 (26.7%)10 (10.1%)Obstructive sleep apnea-n, (%)0.32985 (3.9%)2 (6.7%)3 (3.0%)Asthma-n, (%)0.13483 (2.3%)2 (6.7%)1 (1.0%)Chronic kidney disease-n, (%)0.697210 (7.8%)3 (10.0%)7 (7.1%)**Medications**On ACE-I n, (%)1.000013 (10.1%)3 (10.0%)10 (10.1%)On ARB-n, (%)1.000021 (16.3%)5 (16.7%)16 (16.2%)**Admission**Median systolic blood pressure (IQR)0.1028130.0 (114.0--142.0)122.2 (107.0--139.0)132.0 (116.0--143.0)Median diastolic BP (IQR)0.106876.0 (67.0--87.0)71.5 (64.0--88.0)78.0 (69.0--87.0)Respiratory rate \>20-n, (%)\<.000166 (51.2%)25 (83.3%)41 (41.4%)O2 saturation (without supplemental O2) \<90%-n, (%)\<.000146 (35.7%)24 (80.0%)22 (22.2%)Bilateral infiltrates on CXR-n, (%)0.004484 (65.1%)26 (86.7%)58 (58.6%)Bilateral infiltrates on CT scan-n, (%)--17 (100.0%)2 (100.0%)15 (100.0%)**Laboratory data at admission \[within 24 hours of hospitalization\]**Median WBC count, K/CMM (IQR)0.03326.9 (4.9--9.6)9.0 (6.4--11.7)6.5 (4.6--9.1)WBC \<4.5, K/CMM-n, (%)0.170729 (22.5)4 (13.3)25 (25.3)Median lymphocyte count, %0.055512.0 (8.0--18.0)8.0 (4.0--15.0)13.0 (9.0--18.0)Lymphocyte \<1, %0.732987 (67.4)21 (70.0)66 (66.7)Median platelet count, K/CMM (IQR)0.4335196.0 (153.0--265.0)175.0 (142.0--251.0)198.0 (154.0--265.0)Platelet \<140, K/CMM-n, (%)0.296622 (17.1)7 (23.3)15 (15.2)Median CRP, mg/L (IQR)0.0178136.1 (53.1--202.4)197.0 (119.2--283.2)118.6 (48.6--168.0)Median LDH, IU/L (IQR)0.0003408.0 (321.0--547.0)540.5 (414.5--805.0)373.0 (301.0--483.0)Median Ferritin, ng/mL (IQR)0.0694848.0 (397.0--1606.0)1414.0 (559.5--2603.5)810.0 (362.0--1393.0)Median IL-6, pg/mL (IQR)0.012273.82 (44.04--188.42)148.8 (52.4--1642.0)47.8 (25.1--98.4)Median D-dimer, mg/L of fibrinogen equivalent units (FEU) (IQR)0.05691.0 (0.6--2.3)1.7 (0.9--4.4)0.9 (0.5--2.1)QSOFA score1.0 (0.0--1.0)1.0 (1.0--2.0)0.0 (0.0--1.0)CURB-651.0 (0.0--2.0)1.0 (1.0--2.0)1.0 (0.0--1.0)MEWS2.0 (1.0--4.0)3.0 (2.0--5.0)2.0 (1.0--3.0)**Hospital course**Median of peak CRP, mg/L (IQR)0.0217154.7 (108.0--254.4)262.7 (137.4--333.5)144.6 (76.0--201.1)Median of peak LDH, IU/L (IQR)0.0003493.0 (369.0--686.0)723.0 (559.5--976.5)418.0 (321.0--560.0)Median of peak ferritin, ng/mL (IQR)0.01101379.0 (557.0--1908.0)1602.0 (1131.0--3241.0)1069.0 (494.0--1735.0)Median of peak D-dimer, mg/L (FEU) (IQR)\<.00012.4 (1.0--4.4)4.4 (4.4--4.4)1.5 (0.7--3.3)Positive blood cultures-n, (%)\<.000111 (12.4%)11 (39.3%)0 (0%)Positive lower respiratory tract cultures-n, (%)0.001411 (33.3%)10 (58.8%)1 (6.3%)**Medications**Hydroxychloroquine-n, (%)\<.000183 (64.3%)29 (96.7%)54 (54.6%)Steroids-n, (%)\<.000127 (20.9%)23 (76.7%)4 (4.0%)IL-6 Inhibitor-n, (%)\<.000133 (25.6%)23 (76.7%)10 (10.1%)Remdesivir-n, (%)\<.000115 (11.6%)15 (50.0%)0 (0%)Full dose anticoagulation-n, (%)\<.000133 (25.6%)23 (76.7%)10 (10.1%)Convalescent plasma-n, (%)\<.000113 (10.1%)13 (43.3%)0 (0%)**Outcomes**ARDS-n, (%)\<.000142 (32.6%)30 (100.0%)12 (12.1%)AKI-n, (%)\<.000129 (22.5%)16 (53.3%)13 (13.1%)Suprainfection-n, (%)\<.000114 (10.9%)13 (43.3%)1 (1.0%)Acute Cardiac Injury-n, (%)\<.00019 (7.0%)8 (26.7%)1 (1.0%)Cardiac arrythmia-n, (%)0.08448 (6.2%)4 (13.3%)4 (4.0%)Septic shock-n, (%)\<.000119 (14.7%)17 (56.7%)2 (2.0%)Thrombotic event-n, (%)1.00006 (4.7%)1 (3.3%)5 (5.1%)New onset of dialysis-n, (%)0.13483 (2.3%)2 (6.7%)1 (1.0%)Discharged-n, (%)\<.000195 (73.6%)4 (13.3%)91 (91.9%)Died-n, (%)0.000120 (15.5%)12 (40.0%)8 (8.1%)Still in the hospital-n, (%)\<.000110 (7.8%)10 (33.3%)0 (0%)Median duration from illness onset until death/discharge or last follow up (IQR), days\<.000113.0 (8.0--20.0)24.0 (19.0--34.0)11.0 (8.0--16.0)Median duration of hospital admission to ICU upgrade (IQR), days0.00361.0 (0--2.0)0.0 (0.0--2.0)1.0 (1.0--2.0)Table 2Characteristics of mechanically ventilated COVID-19 patients.Table 2Characteristicsp-valueMechanically ventilated patients (n = 30)Patients who were weaned from the ventilator successfully (n = 6)Patients who failed to be extubated (n = 24)**Demographic**Median age (IQR)- years0.007165.5 (57.0--71.0)48.5 (41.0--57)68.5 (62.5--72.0)Males-n, (%)0.552625 (83.3%)6 (100%)19 (79.2%)Caucasian-n, (%)0.196113 (43.3%)1 (16.7%)12 (50.0%)**Comorbidities**Heart failure-n, (%)1.00002 (6.7%)0 (0%)2 (8.3%)HTN-n, (%)1.000014 (46.7%)3 (50.0%)11 (45.8%)CAD-n, (%)0.55694 (13.3%)0 (0%)4 (16.7%)DM-n, (%)0.371711 (36.7%)1 (16.7%)10 (41.7%)COPD-n, (%)1.00003 (10.0%)0 (0%)3 (12.5%)Obesity-n, (%)0.30038 (26.7%)3 (50.0%)5 (20.8%)OSA-n, (%)0.36552 (6.7%)1 (16.7%)1 (4.2%)Asthma-n, (%)0.36552 (6.7%)1 (16.7%)1 (4.2%)CKD-n, (%)1.00003 (10.0%)0 (0%)3 (12.5%)**Presentation**Median duration of symptoms before being admitted to hospital (IQR), days0.34716.0 (3.0--10.0)5.0 (3.0--7.0%)6.0 (3.0--11.0)Fever-n, (%)0.552625 (83.3%)6 (100.0%)19 (79.2%)Dry cough-n, (%)0.377816 (53.3%)2 (33.3%)14 (58.3%)Productive cough/expectoration-n, (%)1.00005 (16.7%)1 (16.7%)4 (16.7%)Dyspnea-n, (%)0.637121 (70.0%)5 (83.3%)16 (66.7%)Generalized weakness/malaise-n, (%)0.656714 (46.7%)2 (33.3%)12 (50.0%)Nausea-n, (%)1.00002 (6.7%)0 (0%)2 (8.3%)Vomiting-n, (%)--0 (0%)0 (0%)0 (0%)Diarrhea-n, (%)1.00008 (26.7%)1 (16.7%)7 (29.2%)Poor appetite-n, (%)1.00005 (16.7%)1 (16.7%)4 (16.7%)Sore throat-n, (%)1.00005 (16.7%)1 (16.7%)4 (16.7%)Headache-n, (%)0.29017 (23.3%)0 (0%)7 (29.2%)Anosmia-n, (%)1.00002 (6.7%)0 (0%)2 (8.3%)Altered Mental Status-n, (%)1.00002 (6.7%)0 (0%)2 (8.3%)**Medications**On ACE-I-n, (%)1.00003 (10.0%)0 (0%)3 (12.5%)On ARB-n, (%)1.00005 (16.7%)1 (16.7%)4 (16.7%)**Admission**Median SBP (IQR), mmHg0.3529122.0 (107.0--139.0)117.0 (100.0--136.0)123.0 (109.0--141.0)Median DBP (IQR), mmHg1.000071.5 (64.0--88.0)69.5 (60.0--90.0)71.5 (64.0--87.5)RR \> 20/minute-n, (%)1.000025 (83.3%)5 (83.3%)20 (83.3%)O2 sat (w/o supplemental O2) \<90%-n, (%)0.302124 (80.0%)6 (100.0%)18 (75.0%)Bilateral infiltrates on chest x-ray-n, (%)0.556926 (86.7%)6 (100.0%)20 (83.3%)Bilateral infiltrates on computerized tomography scan-n, (%)--2 (100.0%)0 (0%)2 (100.0%)**Laboratory data at admission (within 24 hours of hospitalization)**Median WBC count, K/CMM (IQR)0.07269.0 (6.4--11.7)10.2 (9.3--14.1)8.4 (5.8--11.2)WBC \<4.5, K/CMM-n, (%)0.55694 (13.3)0 (0)4 (16.7)Lymphocyte \<1%-n, (%)0.328721 (70.0)3 (50.0)18 (75.0)Median platelet count, K/CMM (IQR)0.0071175.0 (142.0--251.0)260.5 (191.0--282.0)170.0 (122.5--221.5)Platelet \<140, K/CMM-n, (%)0.29017 (23.3)0 (0)7 (29.2)Median CRP, mg/L (IQR)0.9257197.0 (119.2--283.2)209.7 (124.2--385.6)197.0 (116.0--283.2)Median LDH, IU/L (IQR)1.0000540.5 (414.5--805.0)558.5 (416.0--655.0)540.5 (413.0--879.0)Median Ferritin, ng/mL (IQR)0.07041414.0 (559.0--2603.5)756.0 (390.0--1337.0)1605.5 (651.0--2910.0)Median IL-6, pg/mL (IQR)0.0118148.8 (52.4--1642.0)40.6 (30.0--108.4)334.6 (107.5--3130.8)Median D- dimer, mg/L of fibrinogen equivalent units (IQR)0.18941.7 (0.9--4.4)0.8 (0.7--1.7)2.3 (1.0--4.4)Median HbA1C, mmol/L (IQR)0.51276.2 (5.8--6.9)6.9 (6.1--11.6)5.9 (2.0--6.5)**Hospital course**Median SOFA score on ICU admission (IQR)0.30536.0 (4.0--7.0)4.5 (4.0--6.0)6.0 (4.0--7.0)Median of peak CRP, mg/L (IQR)0.3657262.7 (137.4--333.5)211.8 (141.2--536.5)286.6 (108.0--328.0)Median of peak LDH, IU/L (IQR)1.0000723.0 (559.5--976.5)780.5 (582.0--1084.0)723.0 (537.0--925.0)Median of peak Ferritin, ng/mL (IQR)0.41901602.0 (1131.0--3241.0)1452.0 (408--1822)1609.0 (1240--3846.0)Median of peak D-dimer, mg/L of fibrinogen equivalent units (IQR)0.05394.4 (4.4--4.4)4.4 (3.2--4.4)4.4 (4.4--4.4)Positive blood cultures-n, (%)1.000011 (39.3%)2 (40.0%)9 (39.1%)Positive lower respiratory tract cultures-n, (%)0.485310 (58.8%)2 (100.0%)8 (53.3%)**Medications**HCQ-n, (%)1.000029 (96.7%)6 (100.0%)23 (95.8)Steroids-n, (%)1.000023 (76.7%)5 (83.3%)18 (75.0)IL-6 Inhibitor-n, (%)0.290123 (76.7%)6 (100.0%)17 (70.8%)Remdesivir-n, (%)1.000015 (50.0%)3 (50.0%)12 (50.0%)Full dose anticoagulation-n, (%)0.290123 (76.7%)6 (100.0%)17 (70.8%)Convalescent plasma-n, (%)0.672513 (43.3%)2 (33.3%)11 (45.8%)IL-6 inhibitor administered before intubation-n, (%)0.380812 (40.0%)3 (50.0%)9 (37.5)**Outcomes**ARDS-n, (%)--30 (100.0%)6 (100.0%)24 (100.0%)Severity of ARDS (mild)-n, (%)0.55694 (13.3%)0 (0%)4 (16.7%)Severity of ARDS (moderate)-n, (%)0.30038 (26.7%)3 (50.0%)5 (20.8%)Severity of ARDS (severe)-n, (%)0.659918 (60.0%)3 (50.0%)15 (62.5%)AKI-n, (%)0.377816 (53.3%)2 (33.3%)14 (58.3%)Suprainfection-n, (%)0.672513 (43.3%)2 (33.3%)11 (45.8%)Acute Cardiac Injury-n, (%)0.15508 (26.7%)0 (0%)8 (33.3%)Cardiac arrhythmia-n, (%)0.55694 (13.3%)0 (0%)4 (16.7%)Septic shock-n, (%)0.359817 (56.7%)2 (33.3%)15 (62.5%)Thrombotic event-n, (%)1.00001 (3.3%)0 (0%)1 (4.2%)New onset of dialysis-n, (%)1.00002 (6.7%)0 (0%)2 (8.3%)Discharged-n, (%)0.00054 (13.3%)4 (66.7%)0 (0%)Died-n, (%)0.056812 (40.0%)0 (0%)12 (50.0%)Still in the hospital-n, (%)1.000010 (33.3%)2 (33.3%)8 (33.3%)Median duration from Illness onset until death/discharge or last follow-up (IQR), days0.642324.0 (19.0--34.0)22.5 (20.0--34.0)27.0 (18.0--34.5)Median length of ICU stay, (IQR), days0.369415.5 (10.0--24.0)14.5 (10.0--17.0)16.5 (10.0--25.0)Median duration of hospital admission to ICU upgrade, (IQR), days0.74001.0 (1.0--2.0)1.0 (1.0--2.0)1.0 (1.0--2.0)

4. Results {#sec4}
==========

A total of 129 patients were included in the study; 98 were discharged, 20 died, 10 patients were still in the hospital, and 1 patient was transferred to another hospital at the time of last follow-up. The median age of all patients was 63.0 years (IQR 45.0--72.0), 62.8% were males and 61.2% were Caucasian. The most common comorbidities were hypertension (43.4%), diabetes mellitus (19.4%), and obesity (14.0%). The most common symptoms on admission were fever (79.1%), dry cough (62.8%), and shortness of breath (55.8%). The most common complications were acute respiratory distress syndrome (ARDS, 32.6%), acute kidney injury (AKI, 22.5%), septic shock (14.7%), suprainfection (10.1%), acute cardiac injury (ACI, 7%), and new-onset cardiac arrhythmia (6.2%). Six patients had thrombotic complications: bilateral pulmonary embolism (n = 1), deep venous thrombosis (n = 2), cerebrovascular vascular accident (n = 1), acute popliteal artery occlusion (n = 1), and one patient had an upper extremity deep venous thrombosis (n = 1). A total of 39 patients received ICU level of care during hospitalization. The median duration from hospital admission to ICU upgrade in patients requiring mechanical ventilation was 1.0 day (IQR 1.0--2.0) for those initially admitted to the non-ICU level of care.

4.1. Patients who received invasive mechanical ventilation vs patients who did not receive invasive mechanical ventilation ([Table-1](#tbl1){ref-type="table"}) {#sec4.1}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Out of 129 patients, 23.25% (n = 30) required invasive mechanical ventilation. Respiratory rate (RR) and oxygen (O2) saturation at admission differed statistically between the patients who received invasive mechanical ventilation and who did not receive invasive mechanical ventilation. Median values of inflammatory markers (CRP, LDH, and D-dimer) at admission, and peak values during hospitalization showed statistically significant differences among the patients who received invasive mechanical ventilation and those who did not. QSOFA score, modified early warning score (MEWS), and CURB-65 score are delineated in [Table-1](#tbl1){ref-type="table"}. There was a higher frequency of complications among intubated patients; 100% had ARDS, 56.7% developed septic shock, 53.3% had AKI, 43.3% had suprainfection, and 26.7% had ACI. Of the 16 patients with AKI, 3 patients eventually required renal replacement therapy (RRT). Thrombotic events were more common among patients who did not receive invasive mechanical ventilation as shown in Table- 1. In a multivariate logistic regression analysis, odds of intubation were higher in patients with hypoxemia (oxygen saturation without supplemental oxygen \<90%) at admission, and with elevated ferritin (ng/ml) and D-dimer per unit (mg/L of FEU).

4.2. Patients who were successfully weaned from the ventilator vs the patients who failed to be extubated {#sec4.2}
---------------------------------------------------------------------------------------------------------

30 patients required invasive mechanical ventilation and of those, 6 patients were successfully weaned from the ventilator, 12 patients died, 8 were still intubated and critically ill, 3 were discharged to a long term acute care facility after tracheostomy, and 1 was transferred to another hospital. Median age varied significantly between patients who were successfully weaned off the ventilator and the patients who failed extubation \[48.5 years (41.0--57.0) vs 68.5 years (62.5--72.0); p-value 0.0071\]. Patients who were successfully weaned had lower median values of inflammatory markers (ferritin, IL-6, D-dimer). Rates of complications including severe ARDS (50% vs 62.5%), AKI (33.3% vs 58.3%), suprainfections (33.3 vs 45.8%), septic shock (33.3% vs 62.5%) were lower in successfully weaned patients. None of the successfully weaned patients had ACI, cardiac arrhythmias, new RRT, nor thrombotic events. The median duration from illness onset to discharge in successfully weaned patients was 22.5 days.

5. Discussion {#sec5}
=============

Information regarding the disease trajectory in severe COVID-19 leading to invasive mechanical ventilation is still evolving. A large case series from New York suggested a high mortality rate among intubated patients compared to those who were not \[[@bib5]\]. We retrospectively analyzed whether demographic and clinical characteristics might predict clinical outcomes including extubation among VDAHRF patients. Of the 129 hospitalized patients, 85 patients received supplemental oxygenation via nasal cannula (≥1 day) and 35 patients received high flow oxygen (Median 1 day, IQR 0.0--3.0 days). The patients who had a progressive escalation of oxygen requirements, increased work of breathing (respiratory rate \>30 breaths/minute), and no improvement on \>60 L/min of high flow (HF) oxygen and a fraction of inspired oxygen (FiO2) \>0.9, or hemodynamic instability were intubated. In our study, 23.25% of patients required invasive mechanical ventilation (Table- 1). Pressure regulated volume control (PRVC) with a low tidal volume (6--8 mL/kg), and a goal of plateau pressure \< 30 cmH2O was initially used to keep oxygen saturation above 90%. Ultimately, 20% of these patients were successfully weaned from the ventilator and were discharged (Table- 2). Spontaneous breathing trials (SBT) were performed with pressure support ventilation (PSV 6 cm H2O) for 30--120 min to determine the readiness for extubation. The patients who failed SBT trials had a rapid shallow breathing index \>105 breaths/min/L, RR \> 25--30 breaths/min, desaturation or hemodynamic instability. The overall case-fatality rate among hospitalized COVID-19 patients was 15.5% and noted in our study to be 40% among patients requiring invasive mechanical ventilation. The overall case-fatality rate among hospitalized patients was similar to that reported by studies from Wuhan \[[@bib6]\]. However, the reported mortality rate among intubated patients has varied from study to study. Patients who required invasive mechanical ventilation were more likely to have older age, male gender, coronary artery disease, diabetes, and obesity. All these parameters have been implicated independently with increased in-hospital mortality \[[@bib7]\]. The patients who were weaned from the ventilator successfully were more likely to be younger in age (median age 48.5 years; IQR 41.0--57.0), and none of them had heart failure or CAD. The frequency of obesity and hypertension were not significantly different between patients who were weaned successfully and those who were not. In the absence of effective antivirals against SARS-CoV-2 and rapidly evolving treatment guidelines, 64.3% received hydroxychloroquine, 25.6% received an IL-6 inhibitor (tocilizumab), 25.6% received therapeutic anticoagulation, and 20.9% received moderate to high-intensity intravenous steroids. In addition, 13 patients received compassionate treatment with remdesivir, and 15 received convalescent plasma (CP). Our study found that hypoxemia (oxygen saturation\<90%) on room air at admission was significantly associated with higher odds of mechanical ventilation \[[@bib8]\]. Proposed pathophysiology for severe COVID-19 has included cytokine storm syndrome and multi-organ failure secondary to viremia \[[@bib9]\]. The higher median values of inflammatory markers (ferritin, D-dimer, and IL-6) were observed in the patients who failed to be extubated or died, when compared with the patients who were successfully weaned. These are indicative of a severe hyper-inflammatory state. Of those patients who remained on the ventilator or died, 62.5% had septic shock requiring pressors, 58.3% had acute kidney injury (AKI), 45.8% had a secondary infection, and 33.3% had an acute cardiac injury \[[@bib10]\]. Multivariable logistic regression analysis showed increased odds of intubation associated with hypoxemia (odds ratio 17.23, 95% CI 5.206--57.088; p \< 0.0001), elevated d-dimer by one mg/L of FEU (OR 1.515, 95% CI 5.206--57.088; p = 0.0430) and elevated ferritin by one ng/ml (OR 1.001, 95% CI 1.000--1.001, p = 0.0051) on admission. Results of lung biopsies reported from Italy have shown platelet-fibrin thrombi in the context of coagulopathy in severe COVID-19. This information suggests that anticoagulation should be considered in COVID-19 patients who have an elevated D-dimer level at admission. Our study revealed that in future predictive models, data from our study can be used to help guide clinicians in the identification of those patients who have higher odds of intubation and those who may be weaned from the ventilator successfully. The major limitation of our study is that the data is from a single-center. In addition, there is lack of consistent guidelines for supportive treatment. There is also a small sample size of extubated patients. The retrospective study design resulted in missing laboratory findings. Studies with larger sample sizes and complete follow up will better characterize the course of successful extubation and further validate the clinical impact of our clinical findings.

6. Conclusions {#sec6}
==============

Patients who required invasive mechanical ventilation were more likely to be older, male, obese and have, coronary artery disease, and diabetes. Our study revealed that elevated levels of D-dimer, ferritin and hypoxemia (oxygen saturation \<90%) at admission are associated with increased odds of ventilator-dependent acute hypoxic respiratory failure in (VDAHRF) in COVID-19 patients. The patients who were successfully weaned from the ventilator were more likely to be younger in age (median age 48.5 years; IQR 41.0--57.0), and none of them had heart failure or CAD.
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